MODERN ASPECTS OF ENDOMETRIOSIS TREATMENT. USE OF DIENOGEST
article
OA: diamond
CC0
⤵ 4 in-corpus citations
AI-generated summary
Dienogest effectively treats endometriosis-related pain and prevents relapse with a good safety profile, making it suitable for long-term management.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
AI-generated deep summary
This paper is a narrative overview of modern approaches to treating endometriosis, with particular emphasis on dienogest, drawing on published pharmacodynamic, cellular, and clinical studies. It highlights evidence that dienogest can modulate endometriosis-related biology (including effects on aromatase, prostaglandin production, angiogenesis, apoptosis, progesterone receptor isoforms, inflammation-related pathways, and autophagy) and summarizes clinical observations and comparative work on pain and recurrence outcomes after surgical management, while noting that the included evidence spans diverse study designs. A key limitation is that the article functions as an overview rather than presenting new original analyses, and it relies on the heterogeneity of referenced studies and outcomes. This paper is centrally about endometriosis — it focuses specifically on modern treatment strategies and the use of dienogest in endometriosis.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Dienogest is a highly effective drug for treating the major pain symptoms of endometriosis (chronic pelvic pain, dyspareunia and dysmenorrhea) and preventing a relapse with a high safety profile and good tolerability allowing to indicate it for longterm treatment of the disease. The latest data reflecting the full impact on the various links of the pathogenesis disease testify in favour of the choice of the specified progestagen.
Full text
6,714 characters
· extracted from
oa-doi-fallback
· click to expand
СОВРЕМЕННЫЕ АСПЕКТЫ ЛЕЧЕНИЯ ЭНДОМЕТРИОЗА. ПРИМЕНЕНИЕ ДИЕНОГЕСТА
https://doi.org/10.21518/2079-701X-2017-13-54-56
Аннотация
Об авторах
Е. Г. ХилькевичРоссия
д.м.н.,
Москва
О. И. Лисицына
Россия
Москва
Список литературы
1. Begum T, Chowdhury SR. Aetiology and pathogenesis of endometriosis – a review. Mymensingh Med. J., 2013, 22(1): 218–21.
2. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis, Fertility and Sterility, 2012, 98(3): 511–519.
3. Giudice L, Kao L. Endometriosis. Lancet, 2004, 364(9447): 1789–99.
4. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obs. Gynecol Clin North Am., 1997, 24(2): 235–58.
5. The Practice Committee of the American Society of Reproductive Medicine, Treatment of pelvic pain associated with endometriosis: A committee opinion, Fertil. Steril., 2014, 101(4): 927–935.
6. Nnoaham KE, Hummelshoj L, Webster P,’Hooghe TD, De Cicco Nardone F, De Cicco Nardone C, Jenkinson C, Kennedy SH, Zondervan KT. Impact of endometriosis on quality of life and work productivity: A multicenter study across ten countries, Fertil. Steril., 2011, 96(2)6 366–373.e8.
7. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum. Reprod., 2013, 28(6): 1552–1568.
8. Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills., Fertil. Steril., 2017, 107(3): 533–536.
9. Oettel M, Carol W, Elger W, Kaufmann G, Moore C, Romer W, Klinger G, Schneider B, Schroder J, Sobek L, Walter F, Zimmermann H. A 19-norprogestin without 17(alpha)-ethinyl group II: Dienogest from a pharmacodynamic point of view, Drugs of Today, 1995, 31(7): 517–36.
10. Klipping C, Duijkers I, TA F, SF K, Schuett B. Pharmacodynamic study of four oral dosages of dienogest. Fertility and Sterility, 2010, 94(suppl 1, 4): S181, Abstract P-304.
11. Чернуха Г.Е. Современные прогестагены в лечении эндометриоза (обзор международных исследований). Проблемы репродукции, 2012, 4: 68–71.
12. Yamanaka K, Xu B, Suganuma I, Kusuki I, Mita S, Shimizu Y, Mizuguchi K, Kitawaki J. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E 2 production in human endometriotic stromal cells in spheroid culture. Fertil. Steril., 2012, 97(2): 477–482.
13. Miyashita M, Koga K, Takamura M, Izumi G, Nagai M, Harada M, Hirata T, Hirota Y, Fujii T, Osuga Y. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol. Endocrinol., 2014, 3590, 9: 1–5.
14. G R Attia, K Zeitoun, D Edwards, A Johns, B R Carr, and S E. Bulun, Progesterone receptor isoform A but not B is expressed in endometriosis. J. Clin. Endocrinol. Metab., 2000, 85(8): 2897–2902.
15. Hayashi A, Tanabe A, Kawabe S, Hayashi M, Yuguchi H, Yamashita Y, Okuda K, Ohmichi M. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J. Ovarian Res., 2012, 5(1): 31.
16. Grandi G, Mueller MD, Bersinger NA, Facchinetti F, McKinnon BD. The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis. Gynecol. Endocrinol., 2017, 0(0): 1–4.
17. Grandi G, Mueller M, Bersinger N, Papadia A, Nirgianakis K, Cagnacci A, McKinnon B. Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells. Am. J. Reprod. Immunol., 2016, 76(4): 292–298.
18. Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm. Res., 2016, 65(3): 183–192.
19. Nirgianakis K, Grandi G, McKinnon B, Bersinger N, Cagnacci A, Mueller M. Dienogest mediates midkine suppression in endometriosis. Hum. Reprod., 2016, 31(9): 1981–1986.
20. Choi J, Jo M, Lee E, Lee DY, Choi D. Dienogest enhances autophagy induction in endometriotic cells by impairing activation of AKT, ERK1/2, and mTOR. Fertil. Steril., 2015, 104(3): 655–664.
21. Saito F, Tashiro H, Yamaguchi M, Honda R, Ohba T, Suzuki A, Katabuchi H. Development of a mouse model for testing therapeutic agents: The anticancer effect of dienogest on endometrial neoplasms. Gynecol. Endocrinol., 2016, 32(5): 403–407.
22. Takaesu Y, Nishi H, Kojima J, Sasaki T, Nagamitsu Y, Kato R, Isaka K. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis, J. Obstet. Gynaecol. Res., 2016, 42(9): 1152–1158.
23. Yamanaka A, Hada T, Matsumoto T, Kanno K, Shirane A, Yanai S, Nakajima S, Ebisawa K, Ota Y, Andou M. Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis, Eur. J. Obstet. Gynecol. Reprod. Biol., 2017, 216: 51–55.
24. Maiorana A, Incandela D, Parazzini F, Alio W, Mercurio A, Giambanco L, Alio L. Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience. Arch. Gynecol. Obstet., 2017.
25. Park SY, Kim SH, Chae HD, Kim C-H, Kang BM. Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months, Clin. Exp. Reprod. Med., 2016, 43(4): 215.
26. Adachi K, Takahashi K, Nakamura K, Otake A, Sasamoto N, Miyoshi Y, Shioji M, Yamamoto Y, Fujitani M. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol. Endocrinol., 2016, 32(8): 646–649.
27. Kim SA, Um MJ, Kim HK, Kim SJ, Moon SJ, Jung H. Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis. Obstet. Gynecol. Sci., 2016, 59(6): 506–511.
28. Доброхотова Ю.Э., Гришин И.Г., Ибрагимова Д.М., Нуруллин Р.Ф. Опыт применения Визанны у пациенток с диагностированным эндометриозом. Проблемы репродукции, 2014, 33–35.
29. Ярмолинская М.И., Беженарь В.Ф. Опыт применения диеногеста в комбинированном лечении генитального эндометриоза. Фарматека, 2013, 3: 48–51.
30. García Uranga-Romano A, Hernández-Valencia J, Zárate M, Basavilvazo-Rodríguez MA. Dienogest usefulness in pelvic pain due to endometriosis. A meta-analysis of its effectiveness. Rev Med Inst Mex Seguro Soc., 2017, 55(4) 452–455.
Рецензия
Для цитирования:
Хилькевич ЕГ, Лисицына ОИ. СОВРЕМЕННЫЕ АСПЕКТЫ ЛЕЧЕНИЯ ЭНДОМЕТРИОЗА. ПРИМЕНЕНИЕ ДИЕНОГЕСТА. Медицинский Совет. 2017;(13):54-56. https://doi.org/10.21518/2079-701X-2017-13-54-56
For citation:
Khilkevich EG, Lisitsyna OI. MODERN ASPECTS OF ENDOMETRIOSIS TREATMENT. USE OF DIENOGEST. Meditsinskiy sovet = Medical Council. 2017;(13):54-56. (In Russ.) https://doi.org/10.21518/2079-701X-2017-13-54-56
JATS XML
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (4)
- Hormone therapy for patients with endometriosis: status update on the problem (literature review) 2020
- An innovative approach in the treatment of nodular adenomyosis 2022
- Dienogest therapy: a window of opportunity for endometriosis 2023
- Prevention of endometriosis recurrence after surgical treatment 2023
Cited by (4)
- Dienogest therapy: a window of opportunity for endometriosis 2023
- Prevention of endometriosis recurrence after surgical treatment 2023
- An innovative approach in the treatment of nodular adenomyosis 2022
- Hormone therapy for patients with endometriosis: status update on the problem (literature review) 2020
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK